XLRN Acceleron Pharma Inc

– Presentations span multiple hematologic diseases including myelodysplastic syndromes, beta-thalassemia, multiple myeloma and myelofibrosis –

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that data in six abstracts on the investigational protein therapeutics sotatercept, luspatercept and ACE-1332 will be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition being held in Orlando, Florida on December 5-8, 2015.

Oral presentations

Title:  

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study (Abstract #92)

Session: 637. Myelodysplastic Syndromes – Clinical Studies: New Therapeutic Approaches

Date:

Saturday, December 5th

Time: 12:15 pm EST (Orange County Convention Center, W331) Title:

TGFβ1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis (Abstract #605)

Session: 635. Myeloproliferative Syndromes: Basic Science II Date: Monday, December 7th Time: 11:30 am EST (Orange County Convention Center, W331) Title:

RAP-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in Murine β-Thalassemia (Abstract #751)

Session: 112. Thalassemia and Globin Gene Regulation: Therapeutic Approaches to Thalassemia and Their Mechanisms Date: Monday, December 7th Time: 4:35 pm EST (Orange County Convention Center, Valencia A (W415A)) Title:

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study (Abstract #752)

Session: 112. Thalassemia and Globin Gene Regulation: Therapeutic Approaches to Thalassemia and Their Mechanisms Date: Monday, December 7th Time: 4:45 pm EST (Orange County Convention Center, Valencia A (W415A))  

Poster presentations

Title:  

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study (Abstract #2862)

Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II Date: Sunday, December 6th Time: 6:00 - 8:00 pm EST (Orange County Convention Center, Hall A) Title:

Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (Abstract #4241)

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster III Date: Monday, December 7th Time: 6:00 - 8:00 pm (EST) (Orange County Convention Center, Hall A)

The posters and presentation slides will be available in the “Publications” section on Acceleron’s website (www.acceleronpharma.com).

About Luspatercept

Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Acceleron and Celgene are initiating phase 3 clinical trials that are designed to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the “MEDALIST” study) and in patients with beta-thalassemia (the “BELIEVE” study). For more information, please visit www.clinicaltrials.gov.

About Sotatercept

Sotatercept is an activin receptor type IIA fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-β) superfamily involved in the late stages of erythropoiesis (red blood cell production). Sotatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing sotatercept as part of a global collaboration. Sotatercept is currently in multiple phase 2 clinical trials. For more information, please visit www.clinicaltrials.gov.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151105005617/en/

Acceleron Pharma Inc.Todd James, 617-649-9393Senior Director, Corporate CommunicationsorMedia:Suda Communications LLCMaureen L. Suda, 585-387-9248